Profile data is unavailable for this security.
About the company
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
- Revenue in USD (TTM)0.00
- Net income in USD-106.47m
- Incorporated2009
- Employees106.00
- LocationAura Biosciences Inc80 Guest StreetBOSTON 01235United StatesUSA
- Phone+1 (617) 500-8864
- Fax+1 (302) 655-5049
- Websitehttps://aurabiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytoDyn Inc | 0.00 | -40.35m | 308.71m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 309.08m | 38.00 | -- | 3.86 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 309.84m | 9.00 | -- | 6.29 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| OpGen Inc | 9.00m | 6.70m | 324.73m | 1.00 | 48.58 | 31.72 | 47.12 | 36.08 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 325.20m | 275.00 | -- | 0.0354 | -- | 1.43 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 325.67m | 112.00 | -- | -- | -- | 13.28 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Immuneering Corp | 0.00 | -62.50m | 330.60m | 54.00 | -- | 1.43 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 333.39m | 106.00 | -- | 2.11 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 338.18m | 28.00 | -- | 1.91 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 339.76m | 124.00 | -- | 2.01 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Rezolute Inc | 0.00 | -84.23m | 347.38m | 71.00 | -- | 2.71 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 349.69m | 4.00 | -- | 159.35 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 353.21m | 64.00 | -- | 2.94 | -- | 22.44 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Benitec Biopharma Inc | 0.00 | -46.30m | 354.71m | 19.00 | -- | 1.89 | -- | -- | -1.11 | -1.11 | 0.00 | 5.47 | 0.00 | -- | -- | 0.00 | -34.33 | -79.73 | -35.10 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 354.98m | 123.00 | -- | 44.82 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 356.18m | 25.00 | -- | -- | -- | 380.13 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
Data as of Feb 18 2026. Currency figures normalised to Aura Biosciences Inc's reporting currency: US Dollar USD
54.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Dec 2025 | 6.92m | 11.14% |
| Adage Capital Management LPas of 30 Sep 2025 | 4.88m | 7.86% |
| Long Focus Capital Management LLCas of 30 Sep 2025 | 4.62m | 7.44% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 4.37m | 7.04% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.20m | 5.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.55m | 4.11% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 2.20m | 3.54% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 2.12m | 3.41% |
| Lundbeckfond Invest A/Sas of 30 Sep 2024 | 1.75m | 2.82% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.26m | 2.02% |
More ▼
Data from 11 Apr 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
